News | October 14, 2013

Data Published in EP EuroPace Highlights Differences in CRT-ICD Battery Longevity Across Manufacturers

EP lab crt icd boston scientific europace

October 14, 2013 — An independent study from the University of Pittsburgh Medical Center, published online this week in EP EuroPace, showed significant differences in battery longevity between contemporary cardiac resynchronization therapy defibrillator (CRT-D) devices, and that the Boston Scientific Corp. device has the longest battery life compared to similar brands.

This retrospective, observational study focused on a cohort of 646 patients who were implanted with current models of CRT-D defibrillators between Jan. 1, 2008 and Dec. 31, 2010. The primary endpoints were the rate of battery depletion — reaching elective replacement indicator (ERI) — as well as the time from device implantation to battery depletion as specified by device manufacturer. Overall, study data demonstrated the shortest battery longevity in contemporary Medtronic CRT-D models compared with devices from other manufacturers.

During the follow-up, only four percent of Boston Scientific device batteries had depleted, compared to seven percent from St. Jude and 25 percent from Medtronic (p < 0.001). Moreover, the four-year battery survival rate of the Boston Scientific device was 94 percent, compared to 92 percent from St. Jude and 67 percent from Medtronic (p < 0.001).

"With improved therapies, the majority of today's heart failure patients will outlive their implantable device,” said Kenneth Stein, M.D., chief medical officer, cardiac rhythm management, Boston Scientific. “A recent study showed that nine percent of patients who have a device replacement experienced a complication or device infection.[iii] As patients live longer, the benefit from longer-lasting devices and fewer replacement surgeries becomes increasingly significant."

The study, Battery Longevity in Cardiac Resynchronization Therapy Implantable Cardioverter Defibrillators, was sponsored exclusively by University of Pittsburgh Medical Center. The study was conducted under the leadership of principal investigator Samir Saba, M.D., chief, cardiovascular electrophysiology, University of Pittsburgh Medical Center.

For more information: www.bostonscientific.com, www.europace.oxfordjournals.org

Related Content

Medtronic Begins Pilot Study of Investigational Extravascular ICD System
News | Implantable Cardioverter Defibrillator (ICD) | August 09, 2018
Medtronic plc announced the start of a pilot study of its investigational Extravascular Implantable Cardioverter...
ICD Placements Not Meeting Medicare Coverage Criteria Decline After Overuse Investigation Announced
Feature | Implantable Cardioverter Defibrillator (ICD) | July 11, 2018
Placement of implantable cardioverter defibrillators (ICDs) not meeting Centers for Medicare and Medicaid Services (CMS...
New Tool Predicts Benefits and Risks of Implantable Defibrillator for Heart Failure Patients
News | Implantable Cardioverter Defibrillator (ICD) | July 02, 2018
University of Washington (UW) Medicine cardiologists have developed a tool to predict which heart-failure patients...
Real-World Data Demonstrates Success Of Smart Pass Filter on Boston Scientific S-ICD System
News | Implantable Cardioverter Defibrillator (ICD) | May 16, 2018
Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful reduction of...
Online Message Board Advice on ICDs Reflects Inaccuracies
News | Implantable Cardioverter Defibrillator (ICD) | April 13, 2018
April 13, 2018 — Medical advice about implanted cardiac defibrillators obtained via an online message board appears t
Biotronik U.S. to Distribute Aziyo ECM Envelopes
News | Implantable Cardioverter Defibrillator (ICD) | April 12, 2018
Biotronik U.S. and Aziyo announced a strategic agreement allowing Biotronik to distribute Aziyo's CanGaroo...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD) | September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD) | September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD) | July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD) | June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
Overlay Init